Filtered By:
Source: Heart Rhythm
Condition: Atrial Fibrillation

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 356 results found since Jan 2013.

HRS white paper on atrial fibrillation centers of excellence: Rationale, considerations, and goals
Atrial fibrillation (AF) remains an important global problem.1 –3 AF continues to lead to poor health outcomes, including reduced quality of life (QoL) and increased risks of heart failure, cognitive impairment, stroke, and death.4,5 Moreover, it has a significant financial impact on health care systems and their associated economies.6–8 In order to improve care for patients with AF, there is an increasing recognition that current care must evolve. Health care organizations should move from a system of siloed outpatient and inpatient clinicians and health care facilities to a system of integrated, coordinated, and pati...
Source: Heart Rhythm - May 4, 2020 Category: Cardiology Authors: Jonathan P. Piccini, James Allred, T. Jared Bunch, Thomas F. Deering, Luigi Di Biase, Ayman A. Hussein, William R. Lewis, Suneet Mittal, Andrea Natale, Jose Osorio, Douglas L. Packer, Christian Ruff, Andrea M. Russo, Prashanthan Sanders, Amber Seiler, Dav Source Type: research

Rationale, considerations, and goals for atrial fibrillation centers of excellence: A Heart Rhythm Society perspective
Atrial fibrillation (AF) remains an important global problem.1 –3 AF continues to lead to poor health outcomes, including reduced quality of life (QoL) and increased risks of heart failure, cognitive impairment, stroke, and death.4,5 Moreover, it has a significant financial impact on health care systems and their associated economies.6–8 In order to improve care for patients with AF, there is an increasing recognition that current care must evolve. Health care organizations should move from a system of siloed outpatient and inpatient clinicians and health care facilities to a system of integrated, coordinated, and pati...
Source: Heart Rhythm - May 4, 2020 Category: Cardiology Authors: Jonathan P. Piccini, James Allred, T. Jared Bunch, Thomas F. Deering, Luigi Di Biase, Ayman A. Hussein, William R. Lewis, Suneet Mittal, Andrea Natale, Jose Osorio, Douglas L. Packer, Christian Ruff, Andrea M. Russo, Prashanthan Sanders, Amber Seiler, Dav Source Type: research

EP News: Allied Professionals
Using data from implantable loop recorders (ILRs) inserted in patients with risk factors for stroke but without history of atrial fibrillation (AF), Diederichsen et  al (Circulation 2020; DOI 10.1161/CIRCULATIONAHA.119.044407; PMID 32114796) used simulation techniques to assess how often various rhythm monitors would pick up episodes of AF during regular screening. The patients were part of the LOOP trial (Atrial Fibrillation Detected by Continuous ECG Monitor ing; ClinicalTrials.gov Identifier: NCT02036450).
Source: Heart Rhythm - March 20, 2020 Category: Cardiology Authors: Erica S. Zado Tags: EP News Source Type: research

EP News: Case Reports
Detection of atrial fibrillation (AF) in patients with cryptogenic stroke is critical and impacts treatment approaches. Multiple tools now are available that can detect AF with high sensitivity and specificity. However, continuous monitors often are required to detect subclinical, short, or infrequent AF episodes. Implantable cardiac monitors are expensive, require surgical insertion, and monitor for 2 –3 years on average. These limitations and the lack of broad availability of monitors prompt the need to consider novel approaches to AF risk assessment in patients post cryptogenic stroke.
Source: Heart Rhythm - February 24, 2020 Category: Cardiology Authors: T. Jared Bunch Tags: EP News Source Type: research

EP News: Clinical
Diederichsen et  al (J Am Coll Cardiol 2019;74:2771, PMID 31779791) evaluated the natural history of subclinical atrial fibrillation (AF) in at-risk patients from the general population. The authors studied 590 individuals ≥70 years of age with ≥1 of hypertension, diabetes, previous stroke, or heart failure; w ithout a history of AF; and with long-term implantable loop recorder monitoring. End points included AF burden, AF progression, symptoms, and heart rate during AF. In a total of 685,445 monitoring days, AF lasting ≥6 minutes was detected in 205 participants (35%).
Source: Heart Rhythm - January 20, 2020 Category: Cardiology Authors: N.A. Mark Estes Tags: EP News Source Type: research

Impact of atrial fibrillation/flutter on the in-hospital mortality of ischemic stroke patients
Stroke is the second leading cause of death worldwide. Ischemic strokes, which are caused by atrial fibrillation/flutter (AF) may be more devastating than those without AF.
Source: Heart Rhythm - October 3, 2019 Category: Cardiology Authors: Karsten Keller, Lukas Hobohm, Philip Wenzel, Thomas M ünzel, Christine Espinola-Klein, Mir A. Ostad Source Type: research

Incidence and Causes of In-hospital Outcomes and 30-day Readmissions After Percutaneous Left Atrial Appendage Closure: A United States Nationwide Retrospective Cohort Study Using Claims Data
Percutaneous left atrial appendage closure (p-LAAC) emerged as an option for stroke prevention in atrial fibrillation (AF) patients ’ ineligible for long-term anticoagulation.Real-world data on its in-hospital and 30-day readmission measures are limited.
Source: Heart Rhythm - September 16, 2019 Category: Cardiology Authors: Venkat L.K. Vuddanda, Mohit K. Turagam, Nikita A. Umale, Zubair Shah, Dhanunjaya R. Lakkireddy, Krzysztof Bartus, Finnian R. McCausland, Poonam Velagapudi, Moussa Mansour, E. Kevin Heist Source Type: research

EP News: Allied Professionals
Di Biase et  al (J Am Coll Cardiol 2019;74:1019, PMID 31439209) sought to assess the incidence of thromboembolic (TE) events such as stroke and transient ischemic attack (TIA) in patients with atrial fibrillation (AF) undergoing ablation for AF that included left atrial appendage (LAA) isolation (LAAI). The st udy group comprised all patients who underwent LAAI as part of their ablation strategy and who were without AF 6 months after ablation. All patients were continued on oral anticoagulation (OAC) with either warfarin or direct oral anticoagulant (DOAC) for the first 6 months.
Source: Heart Rhythm - September 15, 2019 Category: Cardiology Authors: Erica S. Zado Tags: EP News Source Type: research

Thromboembolic, Bleeding, and Mortality Risks among Patients with Nonvalvular Atrial Fibrillation Treated with Dual Antiplatelet Therapy versus Oral Anticoagulants: A Population-Based Study
Dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel is used for stroke prevention in patients with atrial fibrillation (AF) when patients refuse to use oral anticoagulants (OAC) in clinical practice. However, there are limited clinical data comparing these treatments.
Source: Heart Rhythm - July 31, 2019 Category: Cardiology Authors: Wallis C.Y. Lau, Ian J. Douglas, Ian C.K. Wong, Liam Smeeth, Gregory Y.H. Lip, Wai K. Leung, Chung-Wah Siu, Bernard M.Y. Cheung, Michael T.C. Mok, Esther W. Chan Source Type: research

Stroke and Dementia Risk in Patients with and without Atrial Fibrillation and Carotid Arterial Disease
We sought to understand the risks of stroke, transient ischemic attack(TIA), and dementia in patients with and without atrial fibrillation (AF) and carotid arterial disease (CD), or a combination of both, and determine if therapies for each disease may influence risks. 11,572 patients were included and matched into 4 groups of 2,893 by the presence of AF and CD. CD and AF augment risk of stroke/TIA and dementia in the general population and the coexistence of both diseases is additive in risk. Ablation of AF was associated with lower risk, the magnitude of which was greater in those with CD.
Source: Heart Rhythm - July 8, 2019 Category: Cardiology Authors: T. Jared Bunch, Tami L. Bair, Brian G. Crandall, Michael J. Cutler, John D. Day, Kevin G. Graves, Victoria Jacobs, Charles Mallender, Jeffrey S. Osborn, J. Peter Weiss, Heidi T. May Source Type: research

EP News: Clinical
Hohnloser et  al (Circulation 2019;139:2315, PMID 30976787) assessed the safety and efficacy of once-daily edoxaban 60 mg (30 mg in patients indicated for dose reduction) vs vitamin K antagonists (VKAs) in patients with atrial fibrillation undergoing catheter ablation in a multinational, multicenter, random ized, open-label, parallel-group trial. Patients were randomized 2:1 to edoxaban vs VKA. The primary end point was the time to first occurrence of all-cause death, stroke, or major bleeding during the period from the end of the ablation procedure to the end of treatment (90 days).
Source: Heart Rhythm - June 24, 2019 Category: Cardiology Authors: N.A. Mark Estes Tags: EP News Source Type: research

The Heart Rhythm Society/American College of Physicians Atrial Fibrillation Screening and Education Initiative
The prevalence of both atrial fibrillation (AF) and stroke is increasing. Stroke is common in AF and can have devastating consequences, especially when AF is unrecognized, and anticoagulation is not initiated.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Lynda E. Rosenfeld, Alpesh Navin Amin, Jonathan C. Hsu, Asa Oxner, Mellanie True Hills, David S. Frankel Source Type: research

Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
Due to very high thromboembolic risk, life-long oral anticoagulation is recommended in all hypertrophic cardiomyopathy (HCM) patients with non-valvular atrial fibrillation (NVAF).1-3 We read with great interest the paper by Tsuda et al.4 who rightly emphasized the importance of HCM on thromboembolism in patients with AF.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Boyoung Joung, Gregory Y.H. Lip Source Type: research